Fundraising Fox
Regulus Therapeutics Inc.
Unicorn exit · $1.7Bacquired by NovartisSan Diego, US · 87,247 employees on LinkedIn · 3 known investors
Find your way into Regulus Therapeutics Inc.
Sign up to see every warm intro you have to Regulus Therapeutics Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Regulus Therapeutics Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Novartis AG April 2025 · $1.7B ($7.00/share cash upfront plus up to $7.00/share CVR, total equity value up to ~$1.7 billion) · source ↗
Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs. Its lead program, farabursen, targeted miR-17 for treating autosomal dominant polycystic kidney disease.
Founders & leadership
NG
Neil GibsonExecutive
KX
Kleanthis XanthopoulosExecutive
Board
BL
B. Lynne ParshallBoard director
MG
Mark G. FolettaBoard director
JM
John MaraganoreBoard director
DE
Douglas E. WilliamsBoard director
WH
William H. RastetterBoard director
DB
David BaltimoreBoard director
BL
Bruce L.A. CarterBoard director
SP
Stelios PapadopoulosBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$80.7M disclosed across 4 rounds · 2014–2021
▶$34.6MraisedDec 2021 · 16 investors · PharmaceuticalsRule 506(b)
▶$34.6MraisedDec 2021 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph HaganExecutive Officer, Director
- Christopher AkerExecutive Officer
- Alice S. HuangDirector
- Cris CalsadaExecutive Officer
- Jake R. NunnDirector
- David BaltimoreDirector
- Denis DryginExecutive Officer
- William H. RastetterDirector
- Pascale WitzDirector
- Kathryn J. CollierDirector
- Stelios PapadopoulosDirector
- Simos SimeonidisDirector
- Hugh RosenDirector
- Offering amount
- $34.6M
- Amount sold
- $34.6M
- Sales commissions
- $2.1M
- Placement agents
- H. C. Wainwright & Co., LLC, SVB Leerink LLC
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.4MraisedDec 2020 · 18 investors · PharmaceuticalsRule 506(b)
▶$19.4MraisedDec 2020 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph HaganExecutive Officer, Director
- Cris CalsadaExecutive Officer
- Christopher AkerExecutive Officer
- Denis DryginExecutive Officer
- Stelios PapadopoulosDirector
- David BaltimoreDirector
- Kathryn J. CollierDirector
- Jake R. NunnDirector
- William H. RastetterDirector
- Hugh RosenDirector
- Simos SimeonidisDirector
- Pascale WitzDirector
- Offering amount
- $34.5M
- Amount sold
- $19.4M
- Sales commissions
- $1.1M
- Placement agents
- H. C. Wainwright & Co., LLC
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.7MraisedMay 2019 · 21 investors · PharmaceuticalsRule 506(b)
▶$16.7MraisedMay 2019 · 21 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph P. HaganExecutive Officer, Director
- Daniel R. ChevallardExecutive Officer
- Christopher AkerExecutive Officer
- David BaltimoreDirector
- Stelios PapadopoulosDirector
- William H. RastetterDirector
- Pascale WitzDirector
- Hugh RosenDirector
- Kathryn L. CollierDirector
- Offering amount
- $79.3M
- Amount sold
- $16.7M
- Sales commissions
- $2.3M
- Placement agents
- H.C. Wainwright Co.
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedFeb 2014 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark G. FolettaDirector
- John MaraganoreDirector
- Douglas E. WilliamsDirector
- William H. RastetterDirector
- David BaltimoreDirector
- Bruce L.A. CarterDirector
- B. Lynne ParshallDirector
- Neil GibsonExecutive Officer
- Stelios PapadopoulosDirector
- Kleanthis XanthopoulosExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Regulus Therapeutics Inc. do?
- Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs. Its lead program, farabursen, targeted miR-17 for treating autosomal dominant polycystic kidney disease.
- Who are Regulus Therapeutics Inc.'s investors?
- Regulus Therapeutics Inc.'s investors include Foresite Capital, New Enterprise Associates (NEA), SR One Capital Management.
- How much funding has Regulus Therapeutics Inc. raised?
- Regulus Therapeutics Inc. has disclosed $80.7M raised across 4 rounds.
- Who acquired Regulus Therapeutics Inc.?
- Regulus Therapeutics Inc. was acquired by Novartis.
- Where is Regulus Therapeutics Inc. headquartered?
- Regulus Therapeutics Inc. is headquartered in San Diego, US.